title: Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma.
abstract: The ring chromosome is a circular, structural abnormality composed of either multiple chromosomes or a single chromosome with loss of genetic material at one or both ends. This chromosomal rearrangement is often unstable with frequent recombinations and may be accompanied by either loss or amplification of genetic material[1]. Considering that ring chromosomes are rare in acute myelogenous leukemia (AML), it is difficult to risk stratify patient prognosis, particularly when the ring chromosome occurs as the sole abnormality. Here we report a case of a ring chromosome 18 abnormality in a patient with newly diagnosed AML with monocytic differentiation. Cytogenetic analysis demonstrated 46, XY, r(18)(p11q21) karyotype in 19 of 34 evaluated metaphase cells. The patient received induction chemotherapy and subsequent allogeneic cord blood transplant from a sex-matched donor, and remained in hematologic and cytogenetic remission for 120 days post transplant. Soon after, he developed post transplant lymphoproliferative disorder and died of multi-organ failure. Although r(18) chromosomal abnormalities were not classified in the recent updated evidence-and expert opinion-based recommendations for the diagnosis and management of AML (likely due to the small number of reported cases), the patient was treated as high risk with stem cell transplantation. This was based on the unstable nature of the ring chromosome and the poor outcomes described in the literature of patients with sole ring 18 abnormalities.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, The Tisch Cancer Institute, The Mount Sinai School of Medicine, New York, NY, USA.
authors.forename: Shanthi
authors.initials: S
authors.lastname: Sivendran
authors.forename: Stephen
authors.initials: S
authors.lastname: Gruenstein
authors.forename: Adriana K
authors.initials: AK
authors.lastname: Malone
authors.forename: Vesna
authors.initials: V
authors.lastname: Najfeld
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002869:Chromosome Aberrations; D002887:Chromosomes, Human, Pair 18 / Q000235:genetics*; D003131:Combined Modality Therapy; D036101:Cord Blood Stem Cell Transplantation; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D008297:Male; D012303:Ring Chromosomes; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents